Literature DB >> 6547663

Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.

L B Sheiner, T H Grasela.   

Abstract

NONMEM, a program package the produces the extended least squares estimates of population parameters for a nonlinear mixed-effect model, has been applied to two data sets from patients routinely receiving phenytoin. A general model for the data is proposed. The models used in previous, standard-method analyses of each data set are compared to the general model using NONMEM. The comparison involves two questions: The first asks whether the parameters estimated previously agree with NONMEM estimates when the original model is used. We find that for fixed-effect parameters they generally do, while for interindividual random-effect parameters the previous methods' estimates appear upward biased relative to NONMEM. Second, the original model per se is compared to the general model by comparing the best fit to each. The general model is clearly superior. NONMEM's ability to distinguish among models, and to precisely estimate their parameters from sparse individual data, is illustrated and verified.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547663     DOI: 10.3109/03602538409015067

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  5 in total

1.  Performance in population models for count data, part I: maximum likelihood approximations.

Authors:  Elodie L Plan; Alan Maloney; Iñaki F Trocóniz; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-04       Impact factor: 2.745

Review 2.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 3.  Mathematical Models in the Description of Pregnane X Receptor (PXR)-Regulated Cytochrome P450 Enzyme Induction.

Authors:  Jurjen Duintjer Tebbens; Malek Azar; Elfriede Friedmann; Martin Lanzendörfer; Petr Pávek
Journal:  Int J Mol Sci       Date:  2018-06-15       Impact factor: 5.923

4.  Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.

Authors:  Fumiyoshi Yamashita; Yukako Sasa; Shuya Yoshida; Akihiro Hisaka; Yoshiyuki Asai; Hiroaki Kitano; Mitsuru Hashida; Hiroshi Suzuki
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

5.  A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.

Authors:  James S McCarthy; Thomas Rückle; Elhadj Djeriou; Cathy Cantalloube; Daniel Ter-Minassian; Mark Baker; Peter O'Rourke; Paul Griffin; Louise Marquart; Rob Hooft van Huijsduijnen; Jörg J Möhrle
Journal:  Malar J       Date:  2016-09-13       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.